Swiss Medtechs Contrast EU MDR ‘Chaos’ With Picture Of US Regulatory Efficiency
The EU is dropping down the list of launch markets for medtech innovation
The ongoing failure of Swiss and European Commission decision makers to resolve the issue of Switzerland’s institutional agreement is hampering EU market access for Swiss innovators like IVDs company Abionic. More pressingly, the EU must address the wider issue of the MDR’s negative impact on innovation and start-ups, says Abionic co-founder Iwan Märki.
